

Reimbursement Submissions
In the current Canadian environment there are four (4) basic types of reimbursement submissions pharmaceutical companies must consider. The largest and most complex reimbursement submission is prepared for the Common Drug Review (CDR). These submissions are required for the reimbursement of any new chemical entity (NCE) by public payers. Recently the CDR decided to also review new indications for old drugs. CDR submissions encompass all Provincial Formularies (excluding
The second type is the Provincial Formulary submission. The Consultants at The JBL Group have performed more than 200 individual submissions to provincial formularies. Although many of the components of these submissions are similar to CDR submissions, they can differ in strategy and they must focus on specific provinces where the manufacturer seeks reimbursement. Any pharmaceutical product that is not considered a new chemical entity (line extensions, old chemical entities and formulation changes).
Submissions to the Liste de médicament, in
The private payer market in
The fourth reimbursement submission is one that is often missed by many companies. The Hospital Submission. Each individual hospital in